DNER and hepatocellular carcinoma: BET inhibitor has also emerged as a promising drug for the treatment of SMARCA4-deficient hepatocellular carcinoma based on preclinical studies (24), indicating that this particular subtype of cancer patients may benefit from precision targeted therapy.